Novavax (NVAX) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Novavax (NVAX) Weakness Over Increased Spending is Unwarranted - FBR
March 1, 2016 7:22 AM ESTFBR Capital analyst, Vernon Bernardino, reiterated his Outperform rating as vaccine developer Novavax (NASDAQ: NVAX) reported 4Q15 financial results and presented highlights of its 2015 accomplishments: completion of enrollment ahead of guidance for the RSV vaccine Phase III study in elderly adults, completion of enrollment in the Phase II rollover study, and initiation of a second RSV vaccine Phase III study (maternal immunization of infants). The analyst believes... More
